Literature DB >> 11342620

CD45 tyrosine phosphatase controls common gamma-chain cytokine-mediated STAT and extracellular signal-related kinase phosphorylation in activated human lymphoblasts: inhibition of proliferation without induction of apoptosis.

N Blank1, M Kriegel, T Hieronymus, T Geiler, S Winkler, J R Kalden, H M Lorenz.   

Abstract

The objective of this study was to test whether CD45 signals can influence signaling processes in activated human lymphoblasts. To this end, we generated lymphoblasts which proliferate in response to common gamma-chain cytokines, but readily undergo apoptosis after cytokine withdrawal. In experiments with the CD45R0 mAb UCHL-1, but not control CD45 mAbs, we found significant inhibition of proliferation. Interestingly, the pan-CD45 mAb GAP8.3, which is most effective in inhibition of OKT-3-mediated proliferation in quiescent lymphocytes, was ineffective in lymphoblasts. Addition of CD3 mAb OKT-3 had no influence on IL-2-mediated proliferation (with or without UCHL-1). In contrast, after addition of OKT-3 to IL-4- and IL-7-stimulated proliferation assays, UCHL-1 signals could not significantly alter cellular proliferation. We did not find induction of apoptosis following CD45R0 signaling. In Western blots using mAbs detecting phosphorylated STAT-3, STAT-5, STAT-6, or extracellular signal-related kinase 1/2, we found that CD45R0 signaling could effectively diminish phosphorylation of these intracellular signaling components. Using RT-PCR, we found that CD45R0 signaling inhibited IL-2 mRNA production without major influence on IL-13, IL-5, or IFN-gamma mRNA levels. Costimulation with OKT-3 and IL-2 optimally induced secretion of IFN-gamma, TNF-alpha, and IL-5, which was not decreased by CD45 signals. In conclusion, we illustrate that CD45R0 signals control early cytokine receptor-associated signaling processes and mRNA and DNA synthesis in activated human lymphoblasts. Furthermore, we show the existence of CD45 epitopes (GAP8.3), which are active and critical for signaling in quiescent lymphocytes, but are nonfunctional in activated human lymphoblasts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342620     DOI: 10.4049/jimmunol.166.10.6034

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Extranuclear detection of histones and nucleosomes in activated human lymphoblasts as an early event in apoptosis.

Authors:  C Gabler; N Blank; T Hieronymus; M Schiller; J H M Berden; J R Kalden; H-M Lorenz
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

2.  Anti-CD45RO suppresses human immunodeficiency virus type 1 replication in microglia: role of Hck tyrosine kinase and implications for AIDS dementia.

Authors:  Mee-Ohk Kim; Hyeon-Sook Suh; Qiusheng Si; Bruce I Terman; Sunhee C Lee
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Interleukin-4 supports interleukin-12-induced proliferation and interferon-gamma secretion in human activated lymphoblasts and T helper type 1 cells.

Authors:  Martin A Kriegel; Theresa Tretter; Norbert Blank; Martin Schiller; Christoph Gabler; Silke Winkler; Joachim R Kalden; Hanns-Martin Lorenz
Journal:  Immunology       Date:  2006-06-06       Impact factor: 7.397

4.  The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.

Authors:  Qun Zhou; Yuan Yao; Solveig G Ericson
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

5.  Different associations of CD45 isoforms with STAT3, PKC and ERK regulate IL-6-induced proliferation in myeloma.

Authors:  Xu Zheng; Allison S Li; Huanyu Zheng; Dongmei Zhao; Dagang Guan; Huawei Zou
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

6.  Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II.

Authors:  Martin A Kriegel; Tobias Lohmann; Christoph Gabler; Norbert Blank; Joachim R Kalden; Hanns-Martin Lorenz
Journal:  J Exp Med       Date:  2004-04-26       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.